검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tralokinumab |
Overview Company | LEO Pharma |
Overview Modality | ANTIBODY |
Overview Target | Atopic Dermatitis |
Overview Indication | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | is still under investigation (5,6) |
MoA Biomarker | biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | pd |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years).. Tralokinumab, an anti-interleukin-13 monoclonal antibody, is effective for atopic dermatitis (AD). However, long-term (one-year) clinical outcomes stratified by age groups have not been sufficiently studied. To… |
Clinical Primary efficacy | ORR 46.962% |
Clinical ORR | -8.322 |
Clinical Result source | ClinicalTrials.gov NCT01629667 |
Clinical Data Tier / Score | A · 57 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tralokinumab |
Overview Company | LEO Pharma |
Overview Modality | ANTIBODY |
Overview Target | Atopic Dermatitis |
Overview Indication | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | is still under investigation (5,6) |
MoA Biomarker | biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | pd |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years).. Tralokinumab, an anti-interleukin-13 monoclonal antibody, is effective for atopic dermatitis (AD). However, long-term (one-year) clinical outcomes stratified by age groups have not been sufficiently studied. To… |
Clinical Primary efficacy | ORR 46.962% |
Clinical ORR | -8.322 |
Clinical Result source | ClinicalTrials.gov NCT01629667 |
Clinical Data Tier / Score | A · 57 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교